These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38152857)

  • 1. Implementation of amotosalen plus ultraviolet A-mediated pathogen reduction for all platelet concentrates in France: Impact on the risk of transfusion-transmitted infections.
    Richard P; Pouchol E; Sandid I; Aoustin L; Lefort C; Chartois AG; Baima A; Malard L; Bacquet C; Ferrera-Tourenc V; Gallian P; Laperche S; Bliem C; Morel P; Tiberghien P
    Vox Sang; 2024 Mar; 119(3):212-218. PubMed ID: 38152857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal analysis of annual national hemovigilance data to assess pathogen reduced platelet transfusion trends during conversion to routine universal clinical use and 7-day storage.
    Pitman JP; Payrat JM; Park MS; Liu K; Corash L; Benjamin RJ
    Transfusion; 2023 Apr; 63(4):711-723. PubMed ID: 36802055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivation of yellow fever virus with amotosalen and ultraviolet A light pathogen-reduction technology.
    Girard YA; Santa Maria F; Lanteri MC
    Transfusion; 2020 Mar; 60(3):622-627. PubMed ID: 31957887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 days.
    Infanti L; Holbro A; Passweg J; Bolliger D; Tsakiris DA; Merki R; Plattner A; Tappe D; Irsch J; Lin JS; Corash L; Benjamin RJ; Buser A
    Transfusion; 2019 Nov; 59(11):3350-3361. PubMed ID: 31574181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transfusion of pathogen-reduced platelet components without leukoreduction.
    Sim J; Tsoi WC; Lee CK; Leung R; Lam CCK; Koontz C; Liu AY; Huang N; Benjamin RJ; Vermeij HJ; Stassinopoulos A; Corash L; Lie AKW
    Transfusion; 2019 Jun; 59(6):1953-1961. PubMed ID: 30919465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypersensitivity transfusion reactions to platelet concentrate: a retrospective analysis of the French hemovigilance network.
    Mertes PM; Tacquard C; Andreu G; Kientz D; Gross S; Malard L; Drouet C; Carlier M; Gachet C; Sandid I; Boudjedir K
    Transfusion; 2020 Mar; 60(3):507-512. PubMed ID: 30907010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Transfusion-Transmitted Bacterial Infections according to German Hemovigilance Data (2011-2020).
    Orru' S; Oberle D; Heiden M; Müller S; Krut O; Funk MB
    Transfus Med Hemother; 2023 Apr; 50(2):144-153. PubMed ID: 37066059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogen reduction of double-dose platelet concentrates from pools of eight buffy coats: Product quality, safety, and economic aspects.
    Rosskopf K; Helmberg W; Schlenke P
    Transfusion; 2020 Sep; 60(9):2058-2066. PubMed ID: 32619068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiling alterations in platelets induced by Amotosalen/UVA pathogen reduction and gamma irradiation--a LC-ESI-MS/MS-based proteomics approach.
    Thiele T; Sablewski A; Iuga C; Bakchoul T; Bente A; Görg S; Völker U; Greinacher A; Steil L
    Blood Transfus; 2012 May; 10 Suppl 2(Suppl 2):s63-70. PubMed ID: 22890270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogen-reduced platelets for the prevention of bleeding.
    Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
    Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light.
    Lanteri MC; Santa-Maria F; Laughhunn A; Girard YA; Picard-Maureau M; Payrat JM; Irsch J; Stassinopoulos A; Bringmann P
    Transfusion; 2020 Jun; 60(6):1319-1331. PubMed ID: 32333396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet safety strategies in Japan: impact of short shelf life on the incidence of septic reactions.
    Satake M; Kozakai M; Matsumoto M; Matsubayashi K; Taira R; Goto N
    Transfusion; 2020 Apr; 60(4):731-738. PubMed ID: 32119134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre.
    Amato M; Schennach H; Astl M; Chen CY; Lin JS; Benjamin RJ; Nussbaumer W
    Vox Sang; 2017 Jan; 112(1):47-55. PubMed ID: 28001297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacterial contamination of platelets for transfusion: strategies for prevention.
    Levy JH; Neal MD; Herman JH
    Crit Care; 2018 Oct; 22(1):271. PubMed ID: 30367640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients.
    Nussbaumer W; Amato M; Schennach H; Astl M; Chen CY; Lin JS; Corash L; Benjamin RJ
    Vox Sang; 2017 Apr; 112(3):249-256. PubMed ID: 28198023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction.
    Kerkhoffs JL; van Putten WL; Novotny VM; Te Boekhorst PA; Schipperus MR; Zwaginga JJ; van Pampus LC; de Greef GE; Luten M; Huijgens PC; Brand A; van Rhenen DJ;
    Br J Haematol; 2010 Jul; 150(2):209-17. PubMed ID: 20507310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transfusion-Transmitted Infections Reported to the National Healthcare Safety Network Hemovigilance Module.
    Haass KA; Sapiano MRP; Savinkina A; Kuehnert MJ; Basavaraju SV
    Transfus Med Rev; 2019 Apr; 33(2):84-91. PubMed ID: 30930009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemical and functional characteristics of stored (double-dose) buffy-coat platelet concentrates treated with amotosalen and a prototype UVA light-emitting diode illuminator.
    Brouard N; Pissenem-Rudwill F; Mouriaux C; Haas D; Galvanin A; Kientz D; Mangin PH; Isola H; Hechler B
    Transfusion; 2023 Oct; 63(10):1937-1950. PubMed ID: 37615493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic efficacy and safety of pathogen-reduced platelet components: Results of a meta-analysis of randomized controlled trials.
    Cid J; Charry P; Lozano M
    Vox Sang; 2024 Mar; 119(3):203-211. PubMed ID: 38181391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient inactivation of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in human apheresis platelet concentrates with amotosalen and ultraviolet A light.
    Hindawi SI; El-Kafrawy SA; Hassan AM; Badawi MA; Bayoumi MM; Almalki AA; Zowawi HM; Tolah AM; Alandijany TA; Abunada Q; Picard-Maureau M; Damanhouri GA; Azhar EI
    Transfus Clin Biol; 2022 Feb; 29(1):31-36. PubMed ID: 34411748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.